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Fig 1. Post-EVAR survival.
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abdominal aortic aneurysm (AAA) were identiﬁed from the American Col-
lege of Surgeons National Surgical Quality Improvement Program 2005-
2011 database. Univariable and multivariable logistic regression analyses
were performed.
Results: An iliac conduit was used in 231 patients (1.6%), while the
remainder had a femoral exposure/percutaneous EVAR. Females
comprised 32% of patients with iliac conduits in contrast to 17% of those
without (P < .0001). Patients with iliac conduits were older and had a lower
body mass index (P < .05). On univariable analysis, patients with iliac con-
duits had a higher incidence of postoperative pneumonia (3.0% vs 1.1%; P ¼
.01), ventilator dependence (4.8% vs 1.0%; P < .0001), renal failure (3.0% vs
0.7%; P < .0001), myocardial infarction (3.9% vs 0.8%; P < .0001), urinary
tract infections (3.5% vs 1.6%; P ¼ .03), peripheral nerve deﬁciency (1.3% vs
0.1%; P ¼ .004), transfusion of >4 units of red blood cells during hospital
stay (17.3% vs 4.8%; P < .0001), return to operating room (9.1% vs 3.7%; P
< .0001), and death (3.0% vs 0.9%; P ¼ .001). On multivariable logistic
regression, after controlling for comorbidities and demographics, use of
an iliac conduit was not signiﬁcantly associated (P > .05) with 30-day mor-
tality or any postoperative complication other than myocardial infarction
(odds ratio, 2.6; 95% conﬁdence interval, 1.2-5.6) and peripheral nerve deﬁ-
ciency (odds ratio, 5.1; 95% conﬁdence interval, 1.2-22.2).
Conclusions: Patients with iliac conduits for EVAR have higher post-
operative morbidity and mortality. For patients with complex iliac disease,
this is a viable alternative to allow EVAR to be performed.
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Objectives: Although the EVAR-2 trial demonstrated no beneﬁt of
endovascular abdominal aortic aneurysm (AAA) repair (EVAR) in high-
risk (HR) patients, EVAR is still performed widely in this patient cohort.
This study compared the midterm outcomes after EVAR in the HR patients
with normal-risk (NR) patients. In turn, these data were compared with the
EVAR-2 data.
Methods: A retrospective review from January 2006 to December
2013 identiﬁed 247 patients (75 HR [30.4%], 172 NR [69.6%]) who un-
derwent elective EVAR for infrarenal AAA in an academic institution and
its afﬁliated Veterans Administration hospital. The same HR criteria used
in the EVAR-2 trial were used. Overall survival, graft-related complications,
and reinterventions were estimated by the Kaplan-Meier method. HR pa-
tient’s outcomes were compared with the EVAR-2 data.Fig 2. Post-EVAR intervention-free survival.Table. Baseline characteristics
Variable
Groups
P value
(NR vs HR) EVAR-2NR HR
Age, mean (SD) years 72.4 (8.4) 71.4 (8.1) .4 76.4 (6.7)
Male sex, % 91 93 .6 85
Baseline creatinine,
mean (SD)
1.1 (0.3) 1.8 (2.3) .01 1.9 (0.3)
Cardiac disease, % 47 79 <.01 67
COPD, % 21 35 .02 N/A
Current cancer Rx, % 0 29 <.01 N/A
Statin, % 72 83 .2 39
Aspirin, % 66 63 .6 58
b-Blocker, % 60 71 .2 N/A
COPD, Chronic obstructive pulmonary disease; HR, high risk; NR, normal
risk; SD, standard deviation.Results: Baseline characteristics are detailed in the Table. Use of
aspirin (63% HR vs 66% NR; P ¼ .6), statin (83% HR vs 72% NR; P
¼ .2), and b-blockers (71% HR vs 60% NR; P ¼ .2) was similar; in the
EVAR-2 trial, the corresponding use of these medications was 58%,
39%, and not available, respectively (Table). Perioperative mortality
(0% HR vs 1.2% LR; P ¼ 1.0) and early complication rates (4% HR
vs 6% LR; P ¼ .8) were similar. In contrast, perioperative mortalityin the EVAR-2 trial was 9%. At a mean follow-up of 3 years, the inci-
dence of reintervention for AAA- or graft-related complications was
7% for HR and 10% for NR patients (P ¼ .5). The 1-, 2- and 4-
year survival in HR (85%, 77%, 65%) was lower than in NR (97%,
97%, 93%; P < .001; Fig 1), but this was more favorable compared
with a 4-year survival of 36% in the EVAR-2 trial. No difference
was seen in long-term reintervention-free survival in HR and NR (P
¼ .8; Fig 2). No late AAA ruptures occurred.
Conclusions: EVAR in HR patients can be performed with excel-
lent early survival and midterm durability results. Although HR pa-
tients have inferior overall survival compared with NR patients, our
data indicate more favorable outcomes compared with the EVAR-2
trial in terms of early mortality and longer-term survival. This may
be, in part, attributable to increased statin use. Therefore, EVAR
may be a feasible treatment option for AAA in HR patients, especially
when coupled with statin use.
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